FOR IMMEDIATE RELEASE
Restoring Vision to the Blind
Latest report from the
Lasker/IRRF Initiative for Innovation in Vision Science
published in TVST
Rockville, Md. (Jan. 7, 2015) – Scientists have long known that species such as amphibians and fish can regenerate retinal cells — so why can’t mammals? This and related questions are the premise for the third report from the Albert and Mary Lasker Foundation and the International Retinal Research Foundation’s 10-year collaboration, recently published in the ARVO journal Translational Vision Science & Technology (TVST).
The special report, entitled Restoring Vision to the Blind: the Lasker/IRRF Initiative for Innovation in Vision Science, is a result of the work and discussions among key leaders in retinal degeneration, ocular genetics, electrophysiology and sensorimotor research, molecular biology, neuro-ophthalmology, nanotechnology and regenerative medicine in a series of workshops and a plenary session that took place over a two-year period.
Their aim was to explore which approaches to restoring sight are most promising and most likely to benefit the greatest number of blind individuals who have lost vision as a result of retinal degenerative disease.
“The notion that restoring vision to the blind is possible has long been thought to be fanciful,” explains John E. Dowling, PhD, FARVO, Gordon and Llura Gund Professor of Neuroscience at Harvard University, who chairs the Lasker/IRRF Initiative for Innovation in Vision Science with the guidance of a Lasker/IRRF Joint Advisory Board and collaborating executives.
“However, beginning as far back as the 1960s, vision scientists began to investigate the possibility of restoring vision to the blind by activating neurons in the visual pathways beyond the eye, namely in the visual cortex.,” says Dowling. “These early experiments showed that it is possible to elicit visual sensations in humans by electrically stimulating neurons in the visual cortex.”
Each of the eight chapters of the report is devoted to a specific topic including visual prostheses, optogenetics, gene therapy, stem cells, endogenous regeneration, neuroprotection, vision aids and endpoints. The chapters describe them in detail with indications as to what the major questions are that need to be addressed and how to go about answering these questions where possible.
The special report is available in TVST as a series of free-access articles, which are fully citable and include supplementary materials.
Translational Vision Science & Technology is a free access, peer-reviewed journal published by the Association for Research in Vision and Ophthalmology. TVST emphasizes multidisciplinary research that bridges the gap between basic research and clinical care and is available at www.tvstjournal.org.
About the Lasker/IRRF Initiative for Innovation in Vision Science
This initiative is a 10-year collaboration that began July 15, 2008 with the goal of identifying knowledge gaps in vision research and developing innovative strategies to advance retinal research and accelerate discovery of sight-saving treatments and prevention of retinal degenerative diseases. The Initiative's first report, Astrocytes and Glaucomatous Neurodegeneration, was published in November 2010. The Initiative then examined diabetic retinopathy, one of the leading causes of visual impairment and blindness in the world, and issued its report, Diabetic Retinopathy: Where We Are and A Path to Progress, in November 2012. John E. Dowling, Gordon and Llura Gund Professor of Neurosciences at Harvard University, chairs the Initiative, and each study is undertaken using a Steering Committee (SC) of bench and clinical scientists with expertise in interdisciplinary fields and the combined skills, knowledge, and experience necessary to identify key issues and hurdles confronting vision scientists. The SC identifies leaders in diverse fields to participate in workshops during which key impediments to research progress are identified. These workshops are followed by a plenary session at which small groups focus on specific targeted areas and develop a framework of innovative multidisciplinary approaches to accelerate discovery and its translation to clinical application. The results of these sessions are published by the Initiative for wide distribution within the research community and to potential funders and other organizations interested in advancing research in retinal degenerative diseases.
Visit us at: